Havunen Riikka, Santos João M, Sorsa Suvi, Rantapero Tommi, Lumen Dave, Siurala Mikko, Airaksinen Anu J, Cervera-Carrascon Victor, Tähtinen Siri, Kanerva Anna, Hemminki Akseli
Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
TILT Biotherapeutics Ltd., Helsinki, Finland.
Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21.
Cancer treatment with local administration of armed oncolytic viruses could potentially induce systemic antitumor effects, or the abscopal effect, as they self-amplify in tumors, induce danger signaling, and promote tumor-associated antigen presentation. In this study, oncolytic adenovirus coding for human tumor necrosis factor alpha (TNF-α) and interleukin-2 (IL-2) Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2 (also known as [a.k.a.] TILT-123) provoked antitumor efficacy in tumors that were injected with Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2 and those that were left non-injected in the same animal. Importantly, the virus was able to travel to distant tumors. To dissect the effects of oncolysis and cytokines, we studied replication-incompetent viruses in mice. Systemic antitumor effects were similar in both models, highlighting the importance of the arming device. The cytokines induced positive changes in immune cell infiltrates and induced the expression of several immune-reaction-related genes in tumors. In addition, Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2 was able to increase homing of adoptively transferred tumor-infiltrating lymphocytes into both injected and non-injected tumors, possibly mediated through chemokine expression. In summary, local treatment with Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2 resulted in systemic antitumor efficacy by inducing immune cell infiltration and trafficking into both treated and untreated tumors. Moreover, the oncolytic adenovirus platform had superior systemic effects over replication-deficient vector through spreading into distant tumors.
通过局部施用武装溶瘤病毒进行癌症治疗可能会诱导全身抗肿瘤效应,即远隔效应,因为它们在肿瘤中自我扩增,诱导危险信号,并促进肿瘤相关抗原呈递。在本研究中,编码人肿瘤坏死因子α(TNF-α)和白细胞介素-2(IL-2)的溶瘤腺病毒Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2(也称为TILT-123)在注射了Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2的肿瘤以及同一动物中未注射的肿瘤中激发了抗肿瘤功效。重要的是,该病毒能够传播到远处的肿瘤。为了剖析溶瘤作用和细胞因子的影响,我们在小鼠中研究了无复制能力的病毒。两种模型中的全身抗肿瘤效应相似,突出了武装装置的重要性。细胞因子诱导免疫细胞浸润发生积极变化,并诱导肿瘤中几种免疫反应相关基因表达。此外,Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2能够增加过继转移的肿瘤浸润淋巴细胞归巢到注射和未注射的肿瘤中,这可能是通过趋化因子表达介导的。总之,用Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2进行局部治疗通过诱导免疫细胞浸润并向已治疗和未治疗的肿瘤中迁移,从而产生全身抗肿瘤功效。此外,溶瘤腺病毒平台通过扩散到远处肿瘤,比复制缺陷型载体具有更强的全身效应。